Funding
Agency: Pfizer
Project Identifier: None
Principal Investigator: Cynthia Owsley, PhD, MSPH
The goal of this project is to evaluate whether MacugenŽ improves
vision under low light levels in age-related macular degeneration
(AMD). MacugenŽ has been shown to preserve and improve
visual acuity. Although visual acuity is very important
to activities of daily living such as reading, other aspects
of visual function are also critical and have been accepted
by FDA as visual outcomes. A clinical hallmark of AMD is
a deterioration of vision under dim illumination. Patients
often complain of a central scotoma under dim illumination
and difficulties adapting to low light levels. These complaints
are reflected in problems in night driving and ambulatory
mobility and reading difficulties in dimly lit environments.
Poor night vision has been linked to an increased risk
of injury due to falls at night and driving cessation.
